Process for preparing 5-[1-(4-chlorophenyl)-methylene]-1-hydroxymethyl-2,2-dimethyl-cyclopentanol

Process for preparing 5-[1-(4-chlorophenyl)-methylene]-1-hydroxymethyl-2,2-dimethyl-cyclopentanol 18-. (canceled)10. The process according to claim 9 , wherein the reaction a) is carried out at a temperature of (−10) to 40° C.11. The process according to claim 9 , wherein the hydrogenation b) is carried out at a temperature of (−10) to 40° C.12. The process according to claim 9 , wherein the reaction is carried out in a solvent or solvent mixture.13. The process according to claim 12 , wherein catalyst claim 12 , temperature and solvent or solvent mixture is selected such that the diol (Ia) is obtained in an excess relative to the diol (Ib).14. The process according to claim 12 , wherein the hydrogenation is carried out in the presence of a di(C-C-alkyl)formamid claim 12 , di(C-C-alkyl)acetamid or in N-methyl-2-pyrrolidone and palladium is used as catalyst. The present invention relates to a process for preparing diols of the formula (Ia) and (Ib)According to EP-A 359 305, compound (Ia) can be obtained by reacting either the corresponding epoxide (VII) or ester (VIII)wherein Rrepresents a hydrogen atom, an alkyl group or a cycloalkyl group, with a reducing agent, preferably a complex metal hydride, at a temperature from 35° C. to reflux temperature. However, these reagents suffer from being hazardous and expensive. EP-A 359 305 also teaches the use of the diols (Ia) and (Ib) for preparing fungicidal active cyclopentane derivatives such as Metconazole.EP-A 474303 discloses a method of selectively preparing the diol (Ia) from the well obtainable 1-(4-chlorobenzyl)-4,4-dimethyl-cyclohex-1-en-3-on (IX)However, this process requires, besides complex metal hydrides, the use of hydrogen per oxide, which requires challenging safety means in a technical plant.Therefore, it was an object of the present invention to provide a commercial feasible process for preparing the diols of the formula (I) from readily available starting materials, with (Ia) being obtained in an excess ...

FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: 217.-. (canceled)18. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or a solvate thereof claim 1 , and a pharmaceutically acceptable carrier.1923.-. (canceled)24. A method of inhibiting PDHK in a mammal claim 1 , comprising administering a pharmaceutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or a solvate thereof to the mammal.25. A method of inhibiting PDHK2 in a mammal claim 1 , comprising administering a pharmaceutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or a solvate thereof to the mammal.26. A method of decreasing the blood glucose level in a mammal claim 1 , comprising administering a pharmaceutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or a solvate thereof to the mammal.27. A method of decreasing lactate level in a mammal claim 1 , comprising administering a pharmaceutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or a solvate thereof to the mammal.28. A method for the treatment or prophylaxis of diabetes claim 1 , diabetic complications claim 1 , insulin resistance syndrome claim 1 , metabolic syndrome claim 1 , hyperglycemia claim 1 , dyslipidemia claim 1 , atherosclerosis claim 1 , ...

SUBSTITUTED POLYFLUORENE COMPOUNDS

The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used. 2. The macromer of claim 1 , wherein the macromer has a molecular weight which is a member selected from the group consisting of about 5 kDa claim 1 , about 6 kDa claim 1 , about 7 kDa claim 1 , about 8 kDa claim 1 , about 9 kDa claim 1 , about 10 kDa claim 1 , about 11 kDa claim 1 , about 12 kDa claim 1 , about 13 kDa claim 1 , about 14 kDa claim 1 , about 15 kDa claim 1 , about 16 kDa claim 1 , about 17 kDa claim 1 , about 18 kDa claim 1 , about 19 kDa claim 1 , about 20 kDa claim 1 , about 21 kDa claim 1 , about 22 kDa claim 1 , about 23 kDa claim 1 , about 24 kDa claim 1 , about 25 kDa claim 1 , about about 26 kDa claim 1 , about 27 kDa claim 1 , about 28 kDa claim 1 , about 29 kDa claim 1 , about 30 kDa claim 1 , about 31 kDa claim 1 , about 32 kDa claim 1 , about 33 kDa claim 1 , about 34 kDa claim 1 , about 35 kDa claim 1 , about 36 kDa claim 1 , about 37 kDa claim 1 , about 38 kDa claim 1 , about 39 kDa claim 1 , about 40 kDa claim 1 , about 41 kDa claim 1 , about 42 kDa claim 1 , about 43 kDa claim 1 , about 44 kDa claim 1 , about 45 kDa claim 1 , about 46 kDa claim 1 , about 47 kDa claim 1 , about 48 kDa claim 1 , about 49 kDa claim 1 , about 50 kDa claim 1 , about 51 kDa claim 1 , about 52 kDa claim 1 , about 53 kDa claim 1 , about 54 kDa claim 1 , about 55 kDa claim 1 , about 56 kDa claim 1 , about 57 kDa claim 1 , about 58 kDa claim 1 , about 59 kDa and about 60 kDa.3. The macromer of claim 1 , wherein Eand/or Eis conjugated to an organic dye.4. The macromer of claim 1 , wherein the macromer has an emission wavelength of about 300 nm to about 500 nm.5. The macromer of claim 1 , wherein each of R claim 1 , R claim 1 , R ...

Partially halogenated, hydroxylated fullerene and allergen adsorbent using the same

Provided are a novel fullerene derivative which can adsorb quickly and efficiently an allergen which may cause a pollen allergy without releasing the allergen again, does not contain a metal or the like which may cause a harmful effect to a human body, and is easily applicable, impregnable, or chemically bondable onto surface of various materials: and a process for producing the same. The fullerene derivative is characterized in that a halogen group and many hydroxyl groups are bonded directly to a fullerene nucleus. In the case that the halogen group is chlorine, the fullerene derivative can be synthesized by a partial hydroxylation of a chlorinated fullerene or a partial chlorination of a hydroxylated fullerene.

Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein. 2. The compound of claim 1 , wherein Rand Rare hydrogen claim 1 , Ris 1-phenylvinyl or 1-phenylethyl claim 1 , and Ris phenyl.3. The compound of claim 1 , wherein Ris alkyl terminally substituted with a hydroxy claim 1 , carboxy claim 1 , or phosphate claim 1 , wherein the hydroxy claim 1 , carboxy claim 1 , or phosphate are optionally further substituted with R.5. The compound of claim 1 , wherein Ris hydroxyl claim 1 , alkyl claim 1 , amino claim 1 , aminoalkyl claim 1 , carbamoyl claim 1 , sulphate claim 1 , sulfonate claim 1 , aminosulfonyl claim 1 , phosphate claim 1 , phosphonate claim 1 , or heterocyclyl claim 1 , wherein Ris optionally substituted with R.7. The compound of claim 6 , wherein{'sup': '1', 'a) X is O, and Ris alkanoyl;'}{'sup': '1', 'b) X is —NH—, and Ris alkanoyl;'}{'sup': '1', 'c) X is O, and Ris aminosulfonyl;'}{'sup': '1', 'd) X is —NH—, and Ris aminosulfonyl;'}{'sup': '1', 'e) X is —(C═O)—, Ris amino;'}{'sup': '1', 'f) X is O, Y is —(C═O)—, Ris amino;'}{'sup': '1', 'g) X is O, Y is —(C═O)—, Z is —NH—, and Ris sulfonate; and'}{'sup': '1', 'h) X is O, Y is —(C═O)—, Z is —NH—, and Ris aminosulfonyl.'}8. The compound of claim 1 , wherein the compound is 5-hexyl-4-phenyl-3a-(1-phenylvinyl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,3a claim 1 ,6 claim 1 ,6a-hexahydropentalen-1-yl sulfamide or salt thereof.9. The compound of claim 1 , wherein the compound is 5-hexyl-4-phenyl-3a-(1-phenylvinyl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,3a claim 1 ,6 claim 1 ,6a-hexahydropentalen-1-yl)acetamide or salt thereof.10. A pharmaceutical composition ...

Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein. 4. The method of claim 3 , wherein{'sup': '1', 'a) X is O, and Ris alkanoyl;'}{'sup': '1', 'b) X is —NH—, and Ris alkanoyl;'}{'sup': '1', 'c) X is O, and Ris aminosulfonyl;'}{'sup': '1', 'd) X is —NH—, and Ris aminosulfonyl;'}{'sup': '1', 'e) X is —(C═O)—, Ris amino;'}{'sup': '1', 'f) X is O, Y is —(C═O)—, Ris amino;'}{'sup': '1', 'g) X is O, Y is —(C═O)—, Z is —NH—, and Ris sulfonate; and'}{'sup': '1', 'h) X is O, Y is —(C═O)—, Z is —NH—, and Ris aminosulfonyl.'}5. The method of claim 1 , wherein the compound is 5-hexyl-4-phenyl-3a-(1-phenylvinyl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,3a claim 1 ,6 claim 1 ,6a-hexahydropentalen-1-yl sulfamide or salt thereof.6. The method of claim 1 , wherein the compound is 5-hexyl-4-phenyl-3a-(1-phenylvinyl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,3a claim 1 ,6 claim 1 ,6a-hexahydropentalen-1-yl)acetamide or salt thereof.7. The method of claim 1 , wherein the cardiovascular disease is cardiovascular disease is selected from coronary artery disease (CAD) claim 1 , angina claim 1 , myocardial infarction claim 1 , stroke claim 1 , hypertensive heart disease claim 1 , rheumatic heart disease claim 1 , cardiomyopathy claim 1 , heart arrhythmia claim 1 , congenital heart disease claim 1 , valvular heart disease claim 1 , carditis claim 1 , aortic aneurysms claim 1 , peripheral artery disease claim 1 , and venous thrombosis.11. The method of claim 10 , wherein{'sup': '1', 'a) X is O, and Ris alkanoyl;'}{'sup': '1', 'b) X is —NH—, and Ris alkanoyl;'}{'sup': '1', 'c) X is O, and Ris aminosulfonyl;'}{'sup': '1', 'd) X is —NH—, ...

FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: 1. (canceled) The present invention relates to a fluorene compound and a pharmaceutical use thereof. More particularly, the present invention relates to a compound for the prophylaxis or treatment of diabetes, cardiovascular diseases, hyperlactacidemia and cancer based on activation of pyruvate dehydrogenase (PDH) by inhibition of pyruvate dehydrogenase kinase (PDHK), and use thereof. Furthermore, the present invention relates to a compound for the prophylaxis or treatment of diabetic complications (e.g., neuropathy, retinopathy, nephropathy, cataract etc.), brain ischemia, cerebral apoplexy or pulmonary hypertension, and use thereof.In tissue, for reaction using energy, for example, biosynthesis, active biological transport, muscle contraction etc., the energy is supplied by hydrolysis of adenosine triphosphate (ATP). ATP is produced by oxidation of metabolic fuel which yields much energy, such as glucose and free fatty acids. In oxidative tissues such as muscle, ATP is mostly produced from acetyl-CoA that enters citric acid cycle. Acetyl-CoA is produced by oxidation of glucose via glycolytic pathway or β oxidation of free fatty acid. An enzyme that plays a pivotal role in controlling acetyl-CoA production from glucose is PDH. PDH catalyses the oxidation of pyruvate to acetyl-CoA and carbon dioxide with concomitant reduction of nicotinamide adenine dinucleotide (NAD) to NADH.PDH is a multienzyme complex ...

FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: 12-. (canceled) The present invention relates to a fluorene compound and a pharmaceutical use thereof. More particularly, the present invention relates to a compound for the prophylaxis or treatment of diabetes, cardiovascular diseases, hyperlactacidemia and cancer based on activation of pyruvate dehydrogenase (PDH) by inhibition of pyruvate dehydrogenase kinase (PDHK), and use thereof. Furthermore, the present invention relates to a compound for the prophylaxis or treatment of diabetic complications (e.g., neuropathy, retinopathy, nephropathy, cataract etc.), brain ischemia, cerebral apoplexy or pulmonary hypertension, and use thereof.In tissue, for reaction using energy, for example, biosynthesis, active biological transport, muscle contraction etc., the energy is supplied by hydrolysis of adenosine triphosphate (ATP). ATP is produced by oxidation of metabolic fuel which yields much energy, such as glucose and free fatty acids. In oxidative tissues such as muscle, ATP is mostly produced from acetyl-CoA that enters citric acid cycle. Acetyl-CoA is produced by oxidation of glucose via glycolytic pathway or β oxidation of free fatty acid. An enzyme that plays a pivotal role in controlling acetyl-CoA production from glucose is PDH. PDH catalyses the oxidation of pyruvate to acetyl-CoA and carbon dioxide with concomitant reduction of nicotinamide adenine dinucleotide (NAD) to NADH.PDH is a multienzyme complex ...

Indane dimer compounds and their pharmaceutical use

Indame dimer compounds and their pharmaceutical use particularly to achieve smooth muscle relaxing activity and/or mast cell stabilising activity and/or anti-inflammatory activity are described.

인단 다이머 화합물 및 그 약학적 용도

화합물 인단 다이머 화합물과 특별히 유연한 근육이완성 및/또는 마스트셀 안정성 및/또는 항염증성을 달성하기 위한 약학적 용도에 관한 것이다.

Method for preparing heterocyclideneacetamide derivatives

본 발명에 의해, 식 (I)로 표시되는 화합물 및 식 (I)의 제조 중간체인 식 (B)로 표시되는 화합물 또는 그의 염의 신규 제조 방법 등이 제공된다.

Polymer

A polymer, for use in an organic light emitting device, comprises asymmetrically substituted repeat units of formula (I (a)): wherein R7 represents a substituent bound to the 9-carbon atom of the fluorene ring through a non-aromatic carbon atom, R 8 , R 9 and R 11 independently in each occurrence represent H or a substituent with the proviso that at least one R 8 is not H; R 10 independently in each occurrence is a substituent; and t in each occurrence is independently 0, 1, 2 or 3. R 7 is preferably a linear alkyl substituted with one or more groups -(Ar 6 )w, wherein each Ar 6 independently represents an optionally substituted aryl or heteroaryl group, and w is at least 1, for example 1, 2 or 3.

polymer

Ein Polymer zur Verwendung in einem Licht emittierenden Bauteil umfasst asymmetrisch substituierte Wiederholeinheiten der Formel (I(a)), wobei R7 einen Substituenten darstellt, der an das 9-Kohlenstoffatom des Fluorenrings durch ein nicht aromatisches Kohlenstoffatom gebunden ist; R8, R9 und R11 unabhängig voneinander bei jedem Vorkommen H oder einen Substituenten mit der Maßgabe darstellen, dass mindestens ein R8 nicht H ist; R19 unabhängig voneinander bei jedem Vorkommen ein Substituent ist und t bei jedem Vorkommen unabhängig voneinander 0, 1, 2 oder 3 ist. R7 ist vorzugsweise ein lineares Alkyl, das durch eine oder mehrere Gruppen -(Ar6)w ersetzt wird, wobei jedes Ar6 unabhängig voneinander eine wahlweise substituierte Aryl- oder Heteroarylgruppe darstellt und w mindestens 1 ist, zum Beispiel 1, 2 oder 3. A polymer for use in a light-emitting device comprises asymmetrically-substituted repeating units of the formula (I (a)), wherein R7 represents a substituent bonded to the 9-carbon atom of the fluorene ring through a non-aromatic carbon atom; R8, R9 and R11 are independently at each occurrence H or a substituent with the proviso that at least one R8 is not H; R19 is independently a substituent at each occurrence, and t is independently 0, 1, 2, or 3 at each occurrence. R 7 is preferably a linear alkyl substituted by one or more groups - (Ar 6) w, wherein each Ar 6 independently represents an optionally substituted aryl or heteroaryl group and w is at least 1, for example 1, 2 or 3.

Polymer

A polymer, for use in an organic light emitting device, comprises asymmetrically substituted repeat units of formula (I (a)): wherein R7 represents a substituent bound to the 9-carbon atom of the fluorene ring through a non-aromatic carbon atom, R 8 , R 9 and R 11 independently in each occurrence represent H or a substituent with the proviso that at least one R 8 is not H; R 10 independently in each occurrence is a substituent; and t in each occurrence is independently 0, 1, 2 or 3. R 7 is preferably a linear alkyl substituted with one or more groups —(Ar 6 )w, wherein each Ar 6 independently represents an optionally substituted aryl or heteroaryl group, and w is at least 1, for example 1, 2 or 3.

Compound containing fluorobiphenyl-yl group and use for liquid crystal material and device production

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Benzocycloheptane and benzoxepine derivatives

FIELD: medicine, pharmaceutics. SUBSTANCE: present invention refers to a compound of formula (I), including any stereochemical isomer forms thereof, or a pharmaceutically acceptable salt thereof, , wherein A is phenyl or 6-member aromatic heterocycle containing 1 or 2 nitrogen atom; wherein said phenyl or 6-member aromatic heterocycle may be optionally condensed with phenyl; Z is CH 2 or O; R 1 is halogen, hydroxyl, C 1-4 alkyl, C 1-4 alkyloxy, or provided A is phenyl, then two neighbour substitutes R 1 may be taken together to produce a radical of formula: -O-CH 2 -O- (a-1) or -O-CH 2 -CH 2 -O- (a-2); R 2 is hydrogen or C 1-4 alkyl; each R 3 and R 4 independently is hydrogen, C 1-6 alkyl, C 1-4 alklyloxyC 1-6 alkyl or phenylC 1-4 alkyl; or R 3 and R 4 taken together with a nitrogen atom whereto attached form a radical of formula or , wherein X 1 is CH 2 or CHOH; and X 2 is CH 2 , O or NR 6 ; R 5 is hydrogen, halogen, C 1-4 alkyl or C 1-4 alkyloxy; R 6 is hydrogen, C 1-4 alkyl, C 1-4 alkylcarbonyl; n is equal to an integer 0, 1 or 2; provided the compound is other than , or a pharmaceutically acceptable salt thereof. EFFECT: compounds are used to treat the diseases the treatment of which is affected, mediated or promoted by GHSlA-r receptor activation The present invention also refers to pharmaceutical compositions and an intermediate compound of formula II: . 22 cl, 10 tbl, 11 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 496 769 (51) МПК C07C C07D C07D C07D C07D C07D ФЕДЕРАЛЬНАЯ СЛУЖБА C07D ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ C07D C07D C07D (12) ОПИСАНИЕ 215/44 (2006.01) 313/08 (2006.01) 405/04 (2006.01) 207/09 (2006.01) 211/14 (2006.01) 241/04 (2006.01) 265/30 (2006.01) 239/24 (2006.01) 213/02 (2006.01) 215/02 (2006.01) C07D A61K A61P A61P (13) C2 317/48 (2006.01) 31/335 (2006.01) 1/00 (2006.01) 25/00 (2006.01) ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2010148433/04, 27.04.2009 (24) Дата начала отсчета срока действия патента: 27.04.2009 2 4 9 6 7 6 9 (85) Дата начала ...

Polymer

用于有机发光器件的聚合物，其包含式（I(a)）的非对称取代的重复单元： 其中R 7 代表通过非芳族碳原子与芴环的9-碳原子结合的取代基，R 8 、R 9 和R 11 在每次出现时独立地代表H或取代基，条件是至少一个R 8 不是H；R 10 在每次出现时独立地为取代基；并且t在每次出现时独立地为0、1、2或3。R 7 优选为取代有一个或多个基团-(Ar 6 ) w 的直链烷基，其中每个Ar 6 独立地代表任选取代的芳基或杂芳基，且w至少为1，例如1、2或3。

FLUORENE COMPOUND, PHARMACEUTICAL COMPOSITIONS, PDHK AND PDHK2 INHIBITORS, TREATMENT METHODS, USES OF THE SAME AND COMMERCIAL KIT

La presente provee un agente para la prevención o el tratamiento de diabetes, complicaciones diabéticas, síndrome de resistencia a la insulina, síndrome metabólico, hiperglucemia, dislipidemia, aterosclerosis, insuficiencia cardíaca, cardiomiopatía, isquemia de miocardio, isquemia cerebral, apoplejía cerebral, hipertensión pulmonar, hiperlactacidemia, enfermedad rnitocondrial, encefalomiopatía mitocondrial o cáncer, a saber, un inhibidor de PDHK y similares. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una de sus sales farmacéuticamente aceptables o uno de su solvatos en donde Ra es (I) un átomo de hidrógeno o (II) un átomo de halógeno; Rb es (I) un átomo de hidrógeno, (II) un átomo de halógeno, (III) un grupo alquilo C1-6 opcionalmente sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del siguiente grupo A, (IV) un grupo alquenilo C2-6 opcionalmente sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del siguiente grupo C, (V) un grupo alquinilo C2-6 opcionalmente sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del siguiente grupo C, (VI) un grupo ciano, (VII) -C(=O)-Rb1 en donde Rb1 es un átomo de hidrógeno o un grupo alquilo C1-6 opcionalmente sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del siguiente grupo B, (VIII) -C(=O)-ORb2 en donde Rb2 es un átomo de hidrógeno o un grupo alquilo C1-6 opcionalmente sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del siguiente grupo B, (IX) -C(=O)-NRb3Rb4, en donde Rb3 y Rb4 son iguales o diferentes y cada uno es un átomo de hidrógeno o un grupo alquilo C1-6 opcionalmente sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del siguiente grupo B, (X) -C(=O)-NRb5-ORb6, en donde Rb5 y Rb6 son iguales o diferentes y cada uno es un átomo de hidrógeno o un grupo alquilo opcionalmente sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del siguiente grupo B, (XI) -ORb7, ...

Water-soluble functionalized fullerenes

Provided herein are water-soluble, functionalized fullerenes, and processes for producing water-soluble, functionalized fullerenes. The process includes sulfonating a fullerene in an acidic solution comprising sulfuric acid to produce a sulfonated fullerene, isolating the sulfonated fullerene from the acidic solution without neutralizing the acidic solution, reacting the sulfonated fullerene with hydrogen peroxide to form a reaction product, and isolating a polyhydroxylated fullerene from the reaction product produced from reacting the sulfonated fullerene with the hydrogen peroxide. The process of producing water-soluble fullerenes further includes functionalizing a polyhydroxylated fullerene with one or more pendant functional groups by reacting the polyhydroxylated fullerene with one or more functional group precursors.

Electron withdrawing group-containing monomer and method for producing the same

A monomer containing an electron-withdrawing group of the present invention is represented by following Formula (a), (b) or (c): wherein A<SUP>1</SUP>, A<SUP>2</SUP>, and A<SUP>3 </SUP>are each a ring; R<SUP>a</SUP>, R<SUP>b</SUP>, R<SUP>c</SUP>, and R<SUP>u </SUP>are the same or different and are each a hydrogen atom or organic group; at least one of R<SUP>s</SUP>, R<SUP>w </SUP>and R<SUP>v</SUP>, at least one of R<SUP>t </SUP>and R<SUP>w1</SUP>, and at least one of the two R<SUP>w2</SUP>s are each an electron-withdrawing group, and the others are each a hydrogen atom or organic group; W<SUP>1 </SUP>is a single bond or linkage group; and n denotes an integer of 2 to 25, where at least two of R<SUP>a</SUP>, R<SUP>b</SUP>, R<SUP>c</SUP>, R<SUP>s</SUP>, R<SUP>t</SUP>, R<SUP>u</SUP>, R<SUP>v</SUP>, R<SUP>w</SUP>, R<SUP>w1</SUP>, R<SUP>w2</SUP>, W<SUP>1</SUP>, and carbon atoms constituting ring A<SUP>1</SUP>, carbon atoms constituting ring A<SUP>2</SUP>, and carbon atoms constituting ring A<SUP>3 </SUP>may be combined to form a ring, respectively. The electron-withdrawing groups in R<SUP>s</SUP>, R<SUP>t</SUP>, R<SUP>v</SUP>, R<SUP>w</SUP>, R<SUP>w1</SUP>, and R<SUP>w2 </SUP>are, for example, groups each containing a fluorine atom. The monomer is useful as a raw material for photoresist polymeric compounds.

Novel Fluoropolymer, Resist Compositions Containing The Same, and Novel Fluoromonomers

본 발명은 하기 화학식 Ma로 표시되는 중합체 주쇄 중에 지방족 단환 구조를 갖는 중합체로서, 구조 단위 M1을 1 내지 99 몰％, 구조 단위 M2a를 1 내지 99 몰％, 구조 단위 N을 0 내지 98 몰％ 포함하는, 수평균 분자량이 500 내지 1000000인 불소 함유 공중합체를 제공하다. 이 불소 함유 공중합체는 우수한 건식 에칭 내성과 진공 자외 영역에서의 투명성을 갖는다. The present invention is a polymer having an aliphatic monocyclic structure in the polymer main chain represented by the general formula Ma, comprising 1 to 99 mol% of structural unit M1, 1 to 99 mol% of structural unit M2a, and 0 to 98 mol% of structural unit N. It provides a fluorine-containing copolymer whose number average molecular weight is 500-1 million. This fluorine-containing copolymer has excellent dry etching resistance and transparency in the vacuum ultraviolet region. <화학식 Ma> <Formula Ma> 식 중, 구조 단위 M1은 탄소수 2 또는 3의 에틸렌성 단량체로서, 1개 이상의 불소 원자를 갖는 단량체로부터 유래하는 구조 단위이고, 구조 단위 M2a는 하기 화학식 a로 표시되는 주쇄 중에 지방족 단환 구조를 형성하는 1종 이상의 구조 단위이며, 구조 단위 N은 구조 단위 M1, M2a와 공중합 가능한 단량체로부터 유래하는 구조 단위이다. In the formula, the structural unit M1 is an ethylenic monomer having 2 or 3 carbon atoms, which is a structural unit derived from a monomer having one or more fluorine atoms, and the structural unit M2a forms an aliphatic monocyclic structure in the main chain represented by the following general formula (a). It is at least one structural unit, and structural unit N is a structural unit derived from the monomer copolymerizable with structural units M1 and M2a. <화학식 a> <Formula a> 식 중, R 1 은 탄화수소기 또는 불소 함유 알킬기로 치환될 수도 있는 환을 형성하는 탄소수 1 내지 8의 2가 탄화수소기, 탄화수소기 또는 불소 함유 알킬기로 치환될 수도 있는 환을 형성하는 탄소수와 산소수의 합계가 2 내지 8인 에테르 결합을 갖는 2가 탄화수소기로 이루어지는 군에서 선택되는 1종 이상의 탄화수소기이고, R 2 는 환을 형성하는 탄소수가 1 내지 3인 알킬렌기이며, R 3 및 R 4 는 동일하거나 또는 상이하며, 모두 탄소수가 1 또는 2인 2가 알킬렌기이고, n1, n2, n3은 동일하거나 또는 상이하며 모두 0 또는 1이다. Wherein R 1 represents a carbon number and an oxygen number forming a ring which may be substituted with a divalent hydrocarbon group having 1 to 8 carbon atoms, a hydrocarbon group or a fluorine-containing alkyl group which may be substituted with a ...

Benzocycloheptane and benzoxepine derivatives

本发明涉及式(I)的化合物，包括其任何立体化学异构体，其中取代基如说明书和权利要求书中所定义；其N-氧化物、其药学上可接受的盐或其溶剂化物；条件是所述化合物不是式(B)或其药学上可接受的盐。要求保护的化合物可用于治疗疾病，所述疾病的治疗通过激活GHS 1A-r受体而受到影响、介导或促进。本发明还涉及其药物组合物及其制备方法。

Polymer

유기 발광 소자에서 사용되기 위한 중합체는 하기 화학식 (Ia)의 비대칭적으로 치환된 반복 단위를 포함한다: (Ia) 상기 식에서 R 7 은 비방향족 탄소 원자를 통해 플루오렌 고리의 9-탄소 원자에 결합된 치환체를 나타내고, R 8 , R 9 , 및 R 11 은 독립적으로 각각의 경우에 수소 또는 치환체를 나타내고, 단 하나 이상의 R 8 은 수소가 아니며, R 10 은 각각의 경우에 독립적으로 치환체이고, t는 각각의 경우에 독립적으로 0, 1, 2 또는 3이다. R 7 은 바람직하게는 하나 이상의 -(Ar 6 ) w 기로 치환된 선형 알킬이고, 이때 Ar 6 은 각각 독립적으로, 임의적으로 치환된 아릴 또는 헤테로아릴기를 나타내고, w는 1 이상, 임의적으로 1, 2 또는 3이다. Polymers for use in organic light emitting devices include asymmetrically substituted repeat units of formula (Ia) (Ia) In the above formula R 7 represents a substituent bonded to the 9-carbon atom of the fluorene ring through a non-aromatic carbon atom, R 8 , R 9 , and R 11 independently represent hydrogen or a substituent in each case, 8 is not hydrogen, R &lt; 10 &gt; is independently in each case a substituent, and t is independently 0, 1, 2 or 3 in each case. R 7 is preferably linear alkyl substituted with one or more - (Ar 6 ) w groups, where each Ar 6 independently represents an optionally substituted aryl or heteroaryl group and w is an integer of 1 or more, Or 3.

Fluorinated adamantane derivative and method for producing the same

Fluorine-containing compound having highly fluorinated norbornane structure, fluorine-containing polymer, and their production methods

本发明提供具有被高度氟化的降冰片烷结构的新的聚合性含氟化合物及由该化合物获得的聚合物。此外，还提供所述化合物和聚合物的制造方法及对于该制造方法有用的新的中间体。化合物(11)、化合物(12)等新化合物(1)及其聚合物。可作为该化合物(1)的制备中间体等的化合物(21)(22)等化合物(2)和化合物(31)(32 M )等化合物(3)及它们的制造方法。其中，Z A ～Z E 表示-CH(-OC(O)C(CH 3 )＝CH 2 )-、-CF 2 -等，W A 及W B 表示F等，Y A ～Y E 表示-CH(-OH)-、-CF(-CH 2 OH)等，X A ～X E 表示-C(O)-、-CF 2 -等。

1, 2-dihydroxy-cyclohex-3, 5-diene cyclic compound and production thereof

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Compounds

NOVEL PYRETHRINOID ESTERS CARRYING AN INDANYLE CORE, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS PESTICIDES

Les composés de formule I : (CF DESSIN DANS BOPI) dans laquelle le radical ACO représente le reste d'un acide utilisé en série pyréthrinode, - Z représente un atome d'hydrogène, un atome d'halogène, un radical alkyle, un radical aryle ou un groupement céto, n représentant le nombre 1, 2 ou 3; - Y en position quelconque sur le noyau aromatique représente un atome d'hydrogène, un atome d'halogène, un radical CF3 , un radical CN, un radical alkyle, un radical aryle, m représentant le nombre 1 ou le nombre 2; - W en position quelconque sur le noyau phényle, représentant soit l'une des valeurs indiquées ci-dessus pour Y, soit un radical NO2 , OCH3 , N3 , N(R4 )2 ou SR5 , R4 et R5 représentant un atome d'hydrogène ou un radical alkyle, p représentant le nombre 1 ou le nombre 2. Les composés de formule I présentent d'intéressantes propriétés pesticides. The compounds of formula I: (CF DRAWING IN BOPI) in which the ACO radical represents the residue of an acid used in the pyrethrinode series, - Z represents a hydrogen atom, a halogen atom, an alkyl radical, a radical aryl or a keto group, n representing the number 1, 2 or 3; - Y in any position on the aromatic nucleus represents a hydrogen atom, a halogen atom, a CF3 radical, a CN radical, an alkyl radical, an aryl radical, m representing the number 1 or the number 2; - W in any position on the phenyl ring, representing either one of the values indicated above for Y, or an NO2, OCH3, N3, N (R4) 2 or SR5, R4 and R5 radical representing a hydrogen atom or an alkyl radical, p representing the number 1 or the number 2. The compounds of formula I exhibit interesting pesticidal properties.

NEW SUBSTITUTED 2-INDANOLS-4 AND PREPARATION OF CORRESPONDING ESTERS

TRIFLUOROMETHYL-1 TETRALINE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE SYNTHESIS OF COMPOUNDS WITH THERAPEUTIC PROPERTIES

Derivatives of trifluoromethyl-1-tetralines having the general formula (I), wherein X is a hydrogen atom, a halogen, a hydroxy group, an alkoxy group from C1 to C8 or an optionally substituted aromatic ring; R1 is a hydrogen atom or an halogen, a hydroxy group, a C1-C8 alkoxy group optionally halogenated, occupying one of the positions (5, 6 or 7), or a methylene-dioxy group occupying the positions 5 and 6 or 6 and 7, and R2 is a hydrogen or an halogen atom, a hydroxy group, a linear or branched C1-C8 alkyl group occupying one of the other positions 5, 6 or 7.

Indene derivatives as pharmaceutical agents

Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

TRIFLUOROMETHYL-1 TETRALINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES

Indene derivatives as pharmaceutical agents

Compounds of formula (Ia): wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5 , and R 6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

24,24-DIFLUORO-1A, 25-DIXYDROXYCHOLECALCIFEROL AND PHARMACEUTICAL COMPOSITION CONTAINING THIS PRODUCT

L'INVENTION CONCERNE L'INDUSTRIE PHARMACEUTIQUE. ELLE A POUR OBJET DE NOUVEAUX DERIVES DE LA VITAMINE D, A SAVOIR LE 24,24-DIFLUORO-1A,25-DIHYDROXYCHOLECALCIFEROL ET LE 24,24-DIFLUORO-1A,25-DI-HYDROXY-5,6-TRANS-CHOLECALCIFEROL. CES COMPOSES ONT UNE ACTIVITE VITAMINOIDE D SENSIBLEMENT EQUIVALENTE A CELLE DU 1A,25-DIHYDROXYCHOLECALCIFEROL, COMME LE MONTRE LEUR APTITUDE A ACCROITRE LE TRANSPORT INTESTINAL DU CALCIUM, A AUGMENTER LE TAUX DE CALCIUM SERIQUE ET A EMPECHER LE RACHITISME. CES COMPOSES SONT PREFERES POUR REMPLACER LA VITAMINE D DANS LE TRAITEMENT D'AFFECTIONS ACCOMPAGNEES DE PERTURBATIONS DU METABOLISME DU CALCIUM ET DU PHOSPHORE. THE INVENTION CONCERNS THE PHARMACEUTICAL INDUSTRY. ITS SUBJECT TO NEW VITAMIN D DERIVATIVES, KNOWING 24,24-DIFLUORO-1A, 25-DIHYDROXYCHOLECALCIFEROL AND 24,24-DIFLUORO-1A, 25-DI-HYDROXY-5,6-TRANS-CHOLECALCIFEROL. THESE COMPOUNDS HAVE A VITAMINOID D ACTIVITY SENSITIVELY EQUIVALENT TO THAT OF 1A, 25-DIHYDROXYCHOLECALCIFEROL, AS SHOWED BY THEIR ABILITY TO INCREASE THE INTESTINAL TRANSPORT OF CALCIUM, TO INCREASE THE LEVEL OF SERUM CALCIUM AND TO PREVENT RACH. THESE COMPOUNDS ARE PREFERRED FOR REPLACING VITAMIN D IN THE TREATMENT OF CONDITIONS ACCOMPANIED BY DISTURBANCES OF CALCIUM AND PHOSPHORUS METABOLISM.

Fluoranthene polymeric compound

A polymer compound comprising a constitutional unit represented by the formula (1): in the formula, Ar 1 represents an aromatic hydrocarbon group or an aromatic heterocyclic group. E represents a group obtained by removing one hydrogen atom in a compound represented by the formula (2): in the formula, R 1 to R 10 represents a hydrogen atom, an alkyl group, an aryl group, a monovalent aromatic heterocyclic group or a group represented by -O-R A . R A represents an alkyl group, an aryl group or a monovalent aromatic heterocyclic group. aa is an integer of 1 or more.

Tetrahydronaphthalene derivatives

Abstract It has been found that the novel tetrahydronaphthalene derivatives of the formula I wherein R1 to R6 and n have the significance given in claim 1. have a pronounced activity in counteracting cerebral insufficiency or improving cognitive functions and also reduce the multiple-resistance towards cytostatics in the treatment of tumours or of chloroquine resistance in the treatment of malaria. They can accordingly be used as medicaments, especially for the control or prevention of cerebral insufficiency or for the improvement of cognitive functions. The novel compounds of formula I can be manufactured by O-acylating a likewise novel compound of the formula

Biochemical process

The production of 1,2-dihydroxy-cyclohexadienes from aromatic compounds by a biochemical process by using strains of Pseudomonas putida, and novel 1,2-disubstituted-cyclo-hexadienes are described. Certain of the novel compounds are useful as intermediates in the production of polymers.

Luminescent layer material, composition for organic electroluminescent element, organic electroluminescent element using these, organic EL display device, and organic EL lighting

Cyclohexenol derivatives

The invention provides cyclohexenol derivatives of the general formula (see formula I) in which n represents an integer from 0 to 5: each R represents a halogen atom, nitro, cyano, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, cycloalkyl or phenyl group: and R1, R2 and R3 independently represent a hydrogen atom or an alkyl group, with the provisos that when R1, R2 and R3 all represent a hydrogen atom then n is not 0 and, when R1, R2 and R3 all represent a hydrogen atom and n is 1, R does not represent a fluorine atom substituted at the 4-position of the phenyl ring: and a process for their preparation. Compounds of formula I are useful as intermediates in the preparation of certain fungicidally active cyclopentane derivatives.

Tetrahydronaphthalene derivates

It was found that the novel tetrahydronaphthalene derivatives of the formula <IMAGE> in which R<1> to R<6> and n have the meaning given in Claim 1, have a pronounced action against cerebral insufficiency or an action improving cognitive functions and are also able to decrease the multiple resistance to cytostatics in the treatment of tumours or chloroquine resistance in the treatment of malaria. They can therefore be used as medicaments, in particular for the control or prevention of cerebral insufficiency or for the improvement of cognitive functions. The compounds of the formula I can be prepared by O-acylation of a likewise novel compound of the formula <IMAGE>

NOVEL PYRETHRINOID ESTERS CARRYING AN INDANYL CORE, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS PESTICIDES

Polymer

本发明涉及聚合物，特别是用于有机发光器件的聚合物，其包含式(I(a))的非对称取代的重复单元： 其中R 7 代表通过非芳族碳原子与芴环的9‑碳原子结合的取代基，R 8 、R 9 和R 11 在每次出现时独立地代表H或取代基，条件是至少一个R 8 不是H；R 10 在每次出现时独立地为取代基；并且t在每次出现时独立地为0、1、2或3。R 7 优选为取代有一个或多个基团‑(Ar 6 ) w 的直链烷基，其中每个Ar 6 独立地代表任选取代的芳基或杂芳基，且w至少为1，例如1、2或3。

Derivatives of Benzocycloheptane and Benzoxepine

1. Соединение формулы ! ! включая любые его стереохимические изомерные формы, где ! A является фенилом, тиенилом, фуранилом или 6-членным ароматическим гетероциклом, содержащим 1 или 2 атома азота; где указанный фенил, тиенил, фуранил или 6-членный ароматический гетероцикл необязательно могут быть сконденсированы с фенилом или 6-членным ароматическим гетероциклом, содержащим 1 или 2 атома азота; ! Z является CH2 или O; ! R1 является галогеном, гидроксилом, C1-4алкилом, C1-4алкилокси, полигалогенC1-4алкилом, циано, нитро, амино, моно- или ди(C1-4алкил)амино; или ! если A является фенилом, два соседних заместителя R1 могут быть взяты вместе с получением радикала формулы: ! -O-CH2-O- (a-1) или ! -O-CH2-CH2-O- (a-2); ! R2 является водородом или C1-4алкилом; ! R3 и R4 каждый независимо является водородом, C1-6алкилом, C1-4алкилоксиC1-6алкилом или фенилC1-4алкилом; или ! R3 и R4, взятые вместе с атомом азота, к которому они присоединены, образуют радикал формулы (b-1) или (b-2) ! , ! где X1 является CH2 или CHOH; и X2 является CH2, O или NR6; ! R5 является водородом, галогеном, C1-4алкилом, C1-4алкилокси или трифторметилом; ! R6 является водородом, C1-4алкилом, C1-4алкилкарбонилом, C1-4алкилоксикарбонилом, фенилоксикарбонилом; ! n равно целому числу 0, 1, 2, 3, 4 или 5; ! его N-оксид, его фармацевтически приемлемая соль или сольват; ! при условии, что соединение не является ! ! или его фармацевтически приемлемой солью. ! 2. Соединение по п.1, где A является фенилом или фенилом, замещенным 1, 2 или 3 заместителями R1. ! 3. Соединение по п.1, где A является радикалом формулы ! ! 4. Соединение по п.1, где A является пиридилом, пиримидинилом или хинолинилом, где каждый из указанных пиридила, пиримидинила или хинолинила не� (19) РОССИЙСКАЯ ФЕДЕРАЦИЯ RU (11) 2010 148 433 (13) A (51) МПК C07C 215/44 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2010148433/04, 27.04.2009 (71) Заявитель(и): ЯНССЕН ФАРМАЦЕВТИКА НВ (BE) ...

Fluoroadamantane derivative

Adamantane derivates which can be material compounds of a polymer excellent in etching resistance and having improved transmittance to light having a short wavelength, are produced by an economically advantageous process from readily available materials. A compound (10) is subjected to esterification reaction with a compound (11) to obtain a compound (12), which is subjected to fluorination in a liquid phase to obtain a compound (13), which is then subjected to hydrolysis or alcoholysis to obtain a compound (2), which is then reacted with a compound (15) thereby to obtain a compound (1). Here, A to J are —CFH— or —CF 2 —; R F is a perfluoroalkyl group or the like; X 10 is F or the like; Y 2 is H or OH; Y 3 is H or R F COO—; Y 4 is H, F or R F COO—; Y 5 is H, F, R F COO— or OH; Y 0 is H, F, —OCOCR 1 ═CH 2 or OH: R 1 is a hydrogen atom, a methyl group or the like; and X 11 is OH or a halogen atom:

Electron-withdrawing group-containing monomer and method for producing the same

本発明の電子吸引性基含有単量体は、下記式（ａ）、（ｂ）又は（ｃ）（式中、Ａ１、Ａ２、Ａ３は環を示し、Ｒａ、Ｒｂ、Ｒｃ、Ｒｕは、同一又は異なって、水素原子又は有機基を示す。Ｒｓ、Ｒｗ及びＲｖのうち少なくとも１つ、Ｒｔ及びＲｗ１のうち少なくとも１つ、２つのＲｗ２のうち少なくとも１つは、それぞれ電子吸引基を示し、残りは水素原子又は有機基を示す。Ｗ１は単結合又は連結基を示し、ｎは２〜２５の整数を示す。Ｒａ、Ｒｂ、Ｒｃ、Ｒｓ、Ｒｔ、Ｒｕ、Ｒｖ、Ｒｗ、Ｒｗ１、Ｒｗ２、Ｗ１、Ａ１環を構成する炭素原子、Ａ２環を構成する炭素原子、Ａ３環を構成する炭素原子は、それぞれ２以上が結合して環を形成していてもよい）で表される。前記Ｒｓ、Ｒｔ、Ｒｖ、Ｒｗ、Ｒｗ１、Ｒｗ２における電子吸引性基は、例えばフッ素原子含有基である。この単量体はフォトレジスト用高分子化合物の原料として有用である。

Polymer

A polymer, for use in an organic light emitting device, comprises asymmetrically substituted repeat units of formula (I (a)): wherein R7 represents a substituent bound to the 9-carbon atom of the fluorene ring through a non-aromatic carbon atom, R8, R9 and R11 independently in each occurrence represent H or a substituent with the proviso that at least one R8 is not H; R10 independently in each occurrence is a substituent; and t in each occurrence is independently 0, 1, 2 or 3. R7 is preferably a linear alkyl substituted with one or more groups -(Ar6)w, wherein each Ar6 independently represents an optionally substituted aryl or heteroaryl group, and w is at least 1, for example 1, 2 or 3.

Patent TW221287B

Indane dimer compounds and their pharmaceutical use

Indane dimer compounds of general formula 5, 6 or 9 and their pharma- ceutical use, particularly to achieve smooth muscle relaxing activity and/or mast cell stabilising activity and/or antiinflammatory activity are described, wherein in formulae 5 and 9, R1 and R3 to R15, and in formula 6, R1, R2 and R4 to R15, are selected from one or more of the same or different of H, halo, h y- droxy, alkoxy, aryloxy acetoxy, carboxy, alkyl carbonyl, hydro carbonyl, amino, amido, alkylamino hydroxylamino, amine oxide groups, azo groups, cyano, hy- drazino groups, hydrazide groups, hydrazone groups, imide groups, iminoether groups, ureyl groups, oxime, nitro, nitrate, nitrite, nitroso groups, nitril e, hete- rocyclic groups containing one or more heteroatoms selected from N, O or S, aralkyl groups, mono and polybenzoid aryl groups, substituted aryl groups, thiol, thioureyl, phenylthiol groups, sulphonic acid groups, sulphoxide groups, sulphone groups, alkyl containing 1 to 10 carbon atoms or cycloalkyl groups containin g 3 to 8 carbon atoms which may be saturated or unsaturated, substituted alkyl or cycloalkyl groups which may be saturated or unsaturated. In formulae 5, 6 an d 9, X is O, NR (wherein R is acyl, alkyl or sulphonate groups), S, SO or SO2. In formulae 5, 6 and 9, any one or more of R1, 1R1; R2,1R2; R3 1R3; R9 1R9; R10 , 1R10 and R14, 1R14 may together represent oxo.

Preparation of cyclic dihydroxy compounds by biochemical processes

ABSTRACT The production of 1,2-dihydroxy-cyclohexadienes from aromatic compounds by a biochemical process by using strains of Pseudomonas putida, and novel 1,2-disubstituted-cyclo-hexadienes are described. Certain of the novel compounds are useful as intermediates in the production of polymers.

Method for constructing fluoride by decarboxylation of alkyl carboxylic acid

本发明涉及有机化合物合成技术领域，特别涉及一种烷基羧酸脱羧构建氟化物的方法。该方法是在热能和/或光能和/或微波条件下，以具有如式 所示结构的烷基羧酸为反应原料，在铁催化剂、配体、含氟试剂、碱的共同作用下，通过自由基脱羧氟化反应得到

Fluorobiphenyl group-containing compound and liquid crystal material of the compound

New method for producing α-ambrinol

Fluorene compound and use thereof for medical purposes

Alicyclic unsaturated compound, polymer, chemically amplified resist composition and method for forming pattern using said composition

A noble alicyclic unsaturated compound represented by the general formula (1): wherein at least one of R 1 and R 2 is a fluorine atom or a fluorinated alkyl group; a polymer formed by the polymerization of a polymer precursor comprising the alicyclic compound. The polymer is useful, in the lithography using a light having a wavelength of 190 nm or less, as a chemically amplified resist which exhibits excellent transparency with respect to the light for use in exposure and also is excellent in the adhesion to a substrate and the resistance to dry etching.

Fluorine-containing compound having highly fluorinated norbornane structure, fluorine-containing polymer, and their production methods

To provide a novel polymerizable fluorocompound having a highly fluorinated norbornane structure, and a polymer obtained from the compound. Further, their production processes and a novel intermediate useful for the processes. A novel compound (1) such as a compound (11) or a compound (12), and its polymer. A compound (2) such as a compound (21) or (22), and a compound (3) such as a compound (31) or (32 M ), which are useful as an intermediate for the production of the compound (1), and its production process. However, each of Z A to Z E represents such as -CH(-OC(O)C(CH 3 )=CH 2 )- or -CF 2 , Each of W A and W E represents such as F, each of Y A to Y E represents such as -CH(-OH)- or -CF(CH 2 OH), and each of X A to X E represents such as -C(O)- or -CF 2 -.

Liquid crystal 1-fluorophenyl-2-cyclohexyl-ethanes

Trans-3-substituted-1-indanol insecticidal ester derivatives

Disclosed are novel compounds of the formula ##STR1## in which R 1 is hydrogen or methyl; R 2 is phenyl or phenyl-methyl either of which is optionally ring substituted with lower alkyl or halogen; R is hydrogen, a tetramethylcyclopropanecarbonyl group, a 1-(substitutedphenyl)-2-methylpropylcarbonyl group, a 1-(4-ethoxyphenyl)-2,2-dichlorocyclopropanecarbonyl group, or a substitutedvinylcyclopropanecarbonyl group; and, with respect to the indanyl substituents, the 1,3-trans isomer is present in an isomeric excess over the corresponding 1,3-cis isomer. The compounds wherein R is other than hydrogen are insecticides, and the compounds wherein R is hydrogen are insecticide intermediates.

Fluorine-containing vitamin d3 analogues

Fluorine-containing vitamin D3 analogues of formula (I), wherein R?1, R2 and R3¿ are independently hydrogen atom, a hydroxy-protecting group, having excellent pharmacological activities, such as tumor cell differentiation-inducing activity, which are useful as a medicament.

3,5-cyclovitamin d compound

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

22indanamine compound

Fluoroadamantane derivative

Adamantane derivates which can be material compounds of a polymer excellent in etching resistance and having improved transmittance to light having a short wavelength, are produced by an economically advantageous process from readily available materials. A compound (10) is subjected to esterification reaction with a compound (11) to obtain a compound (12), which is subjected to fluorination in a liquid phase to obtain a compound (13), which is then subjected to hydrolysis or alcoholysis to obtain a compound (2), which is then reacted with a compound (15) thereby to obtain a compound (1). Here, A to J are —CFH— or —CF 2 —; RF is a perfluoroalkyl group or the like; X 10 is F or the like; Y 2 is H or OH; Y 3 is H or R F COO—; Y 4 is H, F or R F COO—; Y 5 is H, F, R F COO— or OH; Y 0 is H, F, —OCOCR 1 ═CH 2 or OH: R 1 is a hydrogen atom, a methyl group or the like; and X 11 is OH or a halogen atom:

4,4'-(Perfluoroisopropylidene)dicyclohexanol, derivative thereof and process for preparing the same

4,4ʹ-(Perfluoroisopropylidene)dicyclohexanol or its organic acid ester of the formula wherein R¹ is hydrogen atom or acyl group having 1 to 10 carbon atoms, is useful as a starting material of a curable resin, cross-linking agent or the like.

Carbamate derivative compound, preparation method and application thereof

本发明涉及包含氨基甲酸酯衍生物化合物和/或其药学上可接受的盐作为有效成分的用于治疗或预防中枢神经系统(CNS)疾病的药学组合物。并且，本发明涉及治疗或预防中枢神经系统疾病的方法，包括对需要治疗或预防中枢神经系统疾病的个体给药药学有效量的氨基甲酸酯衍生物化合物。

Novel fluorine-containing polymer, resist composition using the same, and novel fluorine-containing monomer

【請求項１】式（Ｍａ）：［式中、構造単位Ｍ１が、炭素数２または３のエチレン性単量体であって少なくとも１個のフッ素原子を有する単量体に由来する構造単位、構造単位Ｍ２ａが、式（ａ）：（式中、Ｒ１は炭化水素基または含フッ素アルキル基で置換されていても良い環を形成する炭素数が１〜８の二価の炭化水素基、炭化水素基または含フッ素アルキル基で置換されていても良い環を形成する炭素数と酸素数の合計が２〜８のエーテル結合を有する二価の炭化水素基よりなる群から選ばれる少なくとも１種の炭化水素基；Ｒ２は環を形成する炭素数が１〜３のアルキレン基；Ｒ３およびＲ４は同じかまたは異なり、いずれも炭素数が１または２の二価のアルキレン基；ｎ１、ｎ２、ｎ３は同じかまたは異なり、いずれも０または１）で示される主鎖中に脂肪族単環構造を形成する少なくとも１種の構造単位、構造単位Ｎは構造単位Ｍ１、Ｍ２ａと共重合可能な単量体に由来する構造単位］で表されるポリマー主鎖中に脂肪族単環構造を有する重合体であって、構造単位Ｍ１を１〜９９モル％、構造単位Ｍ２ａを１〜９９モル％、構造単位Ｎを０〜９８モル％含む数平均分子量が５００〜１００００００の含フッ素共重合体を提供する。該含フッ素共重合体は優れた耐ドライエッチング性と真空紫外領域での透明性を有する。 1. Formula (Ma): [wherein the structural unit M1 is an ethylenic monomer having 2 or 3 carbon atoms and derived from a monomer having at least one fluorine atom, The structural unit M2a is represented by the formula (a): (wherein R1 is a divalent hydrocarbon group having 1 to 8 carbon atoms forming a ring which may be substituted with a hydrocarbon group or a fluorine-containing alkyl group, At least one selected from the group consisting of divalent hydrocarbon groups having an ether bond with a total of 2 to 8 carbon atoms and oxygen atoms forming a ring optionally substituted with a hydrogen group or a fluorine-containing alkyl group Hydrocarbon group; R2 is an alkylene group having 1 to 3 carbon atoms forming a ring; R3 and R4 are the same or different, and each is a divalent alkylene group having 1 or 2 carbon atoms; n1, n2, and n3 are Same or different, both 0 or 1 At least one structural unit that forms an aliphatic monocyclic structure in the main chain, wherein the structural unit N is a structural unit derived from a monomer copolymerizable with the structural units M1 and M2a] A polymer having an aliphatic monocyclic structure in the main chain, comprising 1 to 99 mol% of structural unit M1, 1 to 99 mol% of structural unit M2a, and 0 to 98 mol% of structural unit N Provides a fluorine-containing copolymer having a molecular weight of 500 to 1,000,000. The fluorine-containing copolymer has excellent dry etching ...

Benzofluoranthene-based polymer compound

【課題】最大発光効率に優れる発光素子の製造に有用な高分子化合物を提供する。 【解決手段】式（１）で表される構成単位を含む高分子化合物。 ［式中、Ａｒ 1 は、芳香族炭化水素基、又は、芳香族複素環基を示し、Ｅは、下記一般式（２）から誘導される基を示す。］ 【選択図】なし

NOVEL SUBSTITUTED 2-INDANOLS-4 AND PREPARATION OF CORRESPONDING ESTERS

L'INVENTION CONCERNE DES NOUVEAUX 2-INDANOLS-4 SUBSTITUES ET LEUR APPLICATION A LA PREPARATION DES ESTERS CORRESPONDANTS; LES NOUVEAUX COMPOSES DE L'INVENTION REPONDENT A LA FORMULE GENERALE : (CF DESSIN DANS BOPI) DANS LAQUELLE R REPRESENTE UN RADICAL PHENYLE ET R REPRESENTE UN ATOME D'HYDROGENE. APPLICATION A LA FABRICATION D'ESTERS PRESENTANT DES PROPRIETES INSECTICIDES. THE INVENTION CONCERNS NEW 2-INDANOLS-4 SUBSTITUTES AND THEIR APPLICATION TO THE PREPARATION OF THE CORRESPONDING ESTERS; THE NEW COMPOUNDS OF THE INVENTION MEET THE GENERAL FORMULA: (CF DRAWING IN BOPI) IN WHICH R REPRESENTS A RADICAL PHENYL AND R REPRESENTS A HYDROGEN ATOM. APPLICATION TO THE MANUFACTURE OF ESTERS PRESENTING INSECTICIDAL PROPERTIES.

4,4 '-(Perfluoroisopropylidene) dicyclohexanol and derivatives thereof and process for their production

Benzocycloheptane and benzoxepine derivatives

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than  or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.

Carbamate derivative compound, preparation method and use thereof

본 발명은 카바메이트 유도체 화합물 및/또는 이의 약학적으로 허용 가능한 염을 유효성분으로서 함유하는 CNS 질환 치료 또는 예방용 약학 조성물에 관한 것이다. 또한, 본 발명은 카바ㅍ메이트 유도체 화합물을 CNS 질환의 치료 또는 예방이 필요한 개체에 약학적으로 유효한 양으로 투여하는 것을 포함하는 CNS 질환을 치료 또는 예방하는 방법에 관한 것이다. The present invention relates to a pharmaceutical composition for the treatment or prevention of CNS diseases containing a carbamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient. In addition, the present invention relates to a method for treating or preventing CNS disease, comprising administering a carbamate derivative compound to an individual in need of treatment or prevention of CNS disease in a pharmaceutically effective amount.

Vitamin D3 fluorinated homolog

carbamate derivatives, processes for their preparation and their uses.

a presente invenção refere-se a uma composição farmacêutica para tratamento ou prevenção de distúrbios do snc contendo um composto derivado de carbamato e/ou sal farmaceuticamente aceitável do mesmo co-mo um ingrediente ativo. ainda, a presente invenção refere-se a um método para tratamento ou prevenção de distúrbios do snc compreendendo admi-nistração de um composto derivado de carbamato em uma quantidade far-maceuticamente eficaz a um indivíduo com necessidade de tratamento ou prevenção de distúrbios do snc. The present invention relates to a pharmaceutical composition for treating or preventing SNS disorders containing a carbamate-derived compound and / or a pharmaceutically acceptable salt thereof as an active ingredient. further, the present invention relates to a method for treating or preventing snc disorders comprising administering a carbamate-derived compound in a pharmaceutically effective amount to an individual in need of treating or preventing snc disorders.

Insecticidal(1,1'-biphenyl)-3-ylmethyl esters,their production and use and compositions containing them

Insecticidal and acaricidal pyrethroid esters of formula <CHEM> in which R is one of certain substituted cyclopropyl radicals, A and B are certain halo, haloalkyl, alkyl and alkoxy radicals and a and b are 0, 1, 2, 3, 4 or 5, are novel and may be included in insecticidal and acaricidal compositions and used for killing insects and acarids. They can be in cis or trans configuration. <??>Intermediate compounds in which the <CHEM> residue is replaced by a hydroxy group or a leaving group readily displaced by carboxylate anions are also novel.

Cyclohexenol derivatives

The invention provides cyclohexenol derivatives of the general formula in which n represents an integer from 0 to 5; each R represents a halogen atom, nitro, cyano, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, cycloalkyl or phenyl group; and R 1 , R 2 and R 3 independently represent a hydrogen atom or an alkyl group, with the provisos that when R 1 , R 2 and R 3 all represent a hydrogen atom then n is not 0 and, when R 1 , R 2 and R 3 all represent a hydrogen atom and n is 1, R does not represent a fluorine atom substituted at the 4-position of the phenyl ring; and a process for their preparation. Compounds of formula I are useful as intermediates in the preparation of certain fungicidally active cyclopentane derivatives.

Fluorine-containing compound having highly fluorinated norbornane structure, fluorine-containing polymer, and their production methods

Disclosed are a novel polymerizable fluorine-containing compound having a highly fluorinated norbornane structure and a polymer obtained from such a compound. Also disclosed are their production methods and a novel intermediate useful for the productions. Specifically disclosed are a novel compound (1) such as a compound (11) and a compound (12), and a polymer of the compound (1). Also specifically disclosed are a compound (2) such as compounds (21) and (22) as well as a compound (3) such as compounds (31) and (32M), which are useful as a production intermediate for the compound (1), and their production methods. In this connection, ZA-ZE respectively represent -CH-(-OC(O)C(CH3)=CH2)-, -CF2- or the like; WA and WB respectively represent F or the like; YA-YE respectively represent -CH(-OH)-, -CF(-CH2OH) or the like; and XA-XE respectively represent -C(O)-, -CF2- or the like.

Indane compounds with smooth muscle relaxing and/or mast cell stabilising and/or anti-inflammatory activity

PROCEDURE FOR THE MANUFACTURE OF POLYMER PRODUCTS.

Chiral benzocyclobutene alcohol, and synthesis method and application thereof

本发明公开了一种手性苯并环丁烯醇、其合成方法及用途，该方法是以带有取代基的苯并环丁烯酮1为原料，在钌催化剂、氢供体的共同作用下，进行不对称还原，制备具有手性中心的苯并环丁烯醇化合物，反应方程式如下： 其中，R 1 为取代或未取代的C1‑C20的烃基、苯基、芳基或杂环基，取代基选自碳‑碳双键、碳‑碳三键、酯基、羟基、酰基、酰氧基、酰胺基、卤素、羧基、氰基；所述芳基包含邻、间、对位带有吸电子或给电子取代的苯基，所述吸电子取代基包括卤素、硝基、酯基、羧基、酰基、酰胺基、氰基，所述给电子取代基包括烷基、烯基、苯基、烃氧基、羟基、氨基。本发明反应条件温和，操作简单；底物普适性广；产物具有高对映选择性，且易分离纯化。

PROCEDURE FOR PREPARING A COMPOUND CONTAINING A CIS-1,2-DIHYDROXYCYCLOHEXA-3,5-DIENING RING

Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone

Disclosed herein are methods for preparing steroids and Vitamin D derivatives having the unnatural beta (usually S) configuration at C20, the methods comprising the use of compounds of the formula: wherein R is as defined herein. Also disclosed are steroids and Vitamin D derivatives made using the methods disclosed herein and pharmaceutical compositions comprising said steroids and Vitamin D derivatives.

Indene derivatives as pharmaceutical agents

Disubstituted ethanes and their use in liquid crystal materials and devices

A fluorinated compound having a formula: wherein: R, is hydrogen or alkyl having up to 12 carbon atoms; R 2 is selected from hydrogen, alkyl having up to 12 carbon atoms, alkoxy having up to 12 carbon atoms, wherein R 3 is hydrogen or alkyl having up to 12 carbon atoms, and wherein R 4 is hydrogen, alkyl having up to 12 carbon atoms or alkoxy having up to 12 carbon atoms; represents a cyclohexane ring which is in the trans configuration if 1,4-disubstituted; represents a benzene ring; each of X, Y and Zindependently represents hydrogen or fluorine in one or more of the lateral benzene ring positions, provided that at least one of X, Y and Z is present representing fluorine; n = 0 or 1 provided that when is and R, is alkyl; with the proviso that in Formula l when n is 1 and where R is n-alkyl and R 2 is n-alkyl or n-alkoxy the total number of carbon number of carbon plus oxygen atoms in the two groups R 1 and R 2 is less than 10.

Fullerene derivative, process for production of same, and allergen adsorbent comprising same

Disclosed are: a novel fullerene derivative which can adsorb an allergen that causes hay fever within a short time and with high efficiency and does not re-release the allergen, and which does not contain a metal or the like that has any adverse influence on human bodies, and can be applied onto, can penetrate into or can be chemically bound to surfaces of various materials readily; and a process for producing the fullerene derivative. The fullerene derivative is characterized in that a halogen group and many hydroxy groups are bound directly to a fullerene core. When the halogen group is a chlorine, the derivative can be synthesized by the partial hydroxylation of a chlorinated fullerene or the partial chlorination of a hydroxylated fullerene.

Indene derivatives as pharmaceutical agents

FIELD: chemistry. SUBSTANCE: invention relates to compounds of formula (I) in form of a separate stereoisomer, a mixture of stereoisomers or a racemic mixture of stereoisomers and their pharmaceutically acceptable salts. In formula (I) ring A, C or D is independently completely or partially saturated; each of C1, C4, C11, C12, C15 and C16 is independently substituted with two hydrogen atoms; each of C9 and C14 is independently substituted with a hydrogen atom; R 1 represents -OR 7 or -N(R 7 ) 2 . Values of the rest of the radicals are given in the formula of invention. The invention also relates to a pharmaceutical composition with anti-inflammatory activity and contains an effective amount of the disclosed compound and to use of the said compounds to make a medicinal agent with anti-inflammatory activity. EFFECT: disclosed compounds have anti-inflammatory activity. 23 cl, 47 ex

PROCEDURE FOR PREPARING A COMPOUND CONTAINING A 1,2-DIHYDROXY-CYCLOHEXSA-3,5-DIENRING.

"A PROCEDURE FOR MANUFACTURING A SUBSTITUTED 1,1'-BIPHENYL-3-ILMETILE COMPOUND".

Fluoroadamantane derivative

Adamantane derivates which can be material compounds of a polymer excellent in etching resistance and having improved transmittance to light having a short wavelength, are produced by an economically advantageous process from readily available materials. A compound (10) is subjected to esterification reaction with a compound (11) to obtain a compound (12), which is subjected to fluorination in a liquid phase to obtain a compound (13), which is then subjected to hydrolysis or alcoholysis to obtain a compound (2), which is then reacted with a compound (15) thereby to obtain a compound (1). Here, A to J are —CFH— or —CF 2 —; R F is a perfluoroalkyl group or the like; X 10 is F or the like; Y 2 is H or OH; Y 3 is H or R F COO—; Y 4 is H, F or R F COO—; Y 5 is H, F, R F COO— or OH; Y 0 is H, F, —OCOCR 1 ═CH 2 or OH: R 1 is a hydrogen atom, a methyl group or the like; and X 11 is OH or a halogen atom:

Amines

The method of obtaining derivatives bornilamina

"A PROCEDURE FOR MANUFACTURING A SUBSTITUTED 1,1'-BIPHENYL-3-ILMETILE COMPOUND".

"A PROCEDURE FOR MANUFACTURING A SUBSTITUTED 1,1'-BIPHENYL-3-ILMETILE COMPOUND".

Indane dimer compounds and their pharmaceutical use

Indame dimer compounds and their pharmaceutical use particularly to achieve smooth muscle relaxing activity and/or mast cell stabilising activity and/or anti-inflammatory activity are described.

Fluorene compound and pharmaceutical use thereof

Method for producing heterocyclidene acetamide derivatives

Fluorine-containing aromatic compound and production method thereof

This fluorine-containing aromatic compound is represented in formula (2-1) or formula (2-2). R 1 is a straight-chain perfluoroalkyl group having 1-3 carbon atoms. X 2 -X 5 are halogen atoms or hydrogen atoms, R 2 -R 5 , L 1 and L 2 are a monovalent hydrocarbon group having 1-12 carbon atoms, a monovalent aromatic hydrocarbon group, a monovalent heteroaromatic group, a halogen atom or a hydrogen atom. One or more of R 2 -R 5 is a monovalent hydrocarbon group having 1-12 carbon atoms, a monovalent aromatic hydrocarbon group, or a monovalent heteroaromatic group. Further, m is an integer greater than or equal to 0, n is an integer greater than or equal to 1, and m+n is an integer 2-6.

Indene derivatives as pharmaceutical agents

CYCLIC COMPOUNDS AND PROCEDURE FOR ITS PREPARATION.

EL INVENTO SE REFIERE A UN NUEVO PROCEDIMIENTO PARA LA PRODUCCION DEL COMPUESTO 2-HIDROXI-2,5,5-TRIMETILO-1,2,3,4,4A,5,6,7 PROCEDIMIENTO SE CARACTERIZA PORQUE UN 8-HALO-2-HIDROXI-2, 5, 5-TRIMETILO-2,3,4,4A,5,6,7,8 ONAFTALINA Y LA MEZCLA SE REDUCE A UN NUEVO A 1,2 THE INVENTION REFERS TO A NEW PROCEDURE FOR THE PRODUCTION OF COMPOUND 2-HYDROXY-2,5,5-TRIMETILO-1,2,3,4,4A, 5,6,7 PROCEDURE IS CHARACTERIZED BECAUSE AN 8-HALO-2 -HYDROXY-2, 5, 5-TRIMETILO-2,3,4,4A, 5,6,7,8 ONAFTALINA AND THE MIXTURE IS REDUCED TO A NEW 1,2

Production of cyclic dihydroxy compounds

Process and polymers.

A process for the preparation of aromatic polymers from polymers and copolymers of certain 1,2-disubstituted-cyclohexadienes, particularly in the form of inter alia fibres or films, and novel aromatic polymers.

ENSEKTISID (1.1'-BIFENIL) -3-ILMETIL ESTERS

Alicyclic unsaturated compound, polymer, chemically amplified resist composition and method for forming pattern using said composition

A novel alicyclic unsaturated compound represented by the general formula (1): wherein at least one of R1 and R2 is a fluorine atom or a fluorinated alkyl group; a polymer formed by the polymerization of a polymer precursor comprising the alicyclic unsaturated compound. The polymer is useful, in the lithography using a light having a wavelength of 190 nm or less, as a chemically amplified resist which exhibits excellent transparency with respect to the light for use in exposure and also is excellent in the adhesion to a substrate and the resistance to dry etching.